GlobeNewswire by notified

Scandinavian Tobacco Group A/S reports Q3 results in line with expectations and maintains full year guidance

Share

Company Announcement
No. 54/2021

                                                                                                       Copenhagen, 4 November 2021

Interim report, 1 January - 30 September 2021

Scandinavian Tobacco Group A/S reports Q3 results in line with expectations and maintains full year guidance

For the third quarter of 2021 Scandinavian Tobacco Group delivered strong results against difficult 2020 comparisons. Organic net sales declined by 2% and organic EBITDA grew 1%. The results were driven by continued strong demand for handmade cigars in the US, a favourable market- and product mix, and synergies from the integration of Agio Cigars. Supply issues in Europe impacted net sales negatively in the third quarter.   

Q3 Highlights

  • Net sales were DKK 2,182 million (DKK 2,231 million) with -2.2% organic growth.
  • EBITDA before special items was DKK 627 million (DKK 614 million) with 0.9% organic growth. The EBITDA margin was 28.7% (27.5%).
  • Organic EBITDA growth is positively impacted by a DKK 31 million income from certain duty refunds in the US.
  • Adjusted Earnings Per Share (EPS) were DKK 4.2 (DKK 4.0).
  • Free cash flow before acquisitions was DKK 564 million (DKK 609 million).
  • Return on Invested Capital was 12.9% (9.1%).
  • In the first 9 months of 2021, net sales grew by 5.4% organically to DKK 6,221 million (DKK 6,084 million), and EBITDA before special items grew by 19.5% organically to DKK 1,759 million (DKK 1,429 million) with free cash flow before acquisitions stable at DKK 1,086 million (DKK 1,156 million).

CEO Niels Frederiksen: “We deliver strong quarterly performance in line with expectations and maintain the positive momentum we have had throughout 2020 and 2021. The combination of the integration of Agio Cigars, the growth in handmade cigars and our underlying transformation have significantly improved our performance and raised our earnings and margins levels. I remain proud and impressed with the way our organization has continued to deliver a strong performance throughout a challenging period”.  

Based on the results for the first nine months of 2021 the financial outlook for the full year is unchanged:

  • EBITDA: Organic growth in the range of 16%-20%
  • Free cash flow before acquisitions: In the range of DKK 1.0-1.3 billion
  • Adjusted Earnings Per Share >35% increase

For further information, please contact:
Investors: Torben Sand, Head of IR, phone +45 5084 7222 or torben.sand@st-group.com

Media: Simon Mehl Augustesen, Director of Group Communications, phone: +1 484-379-8725 or simon.augustesen@st-group.com

A conference call will be held on 4 November 2021 at 10.00 CEST. Dial-in information and an accompanying presentation will be available at investor.st-group.com around 09:00 CEST.

Attachment

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Saniona Chairman J. Donald deBethizy and CEO Rami Levin, as well as additional members of the board and management, purchase Saniona shares in the open market2.12.2021 22:45:00 CET | Press release

PRESS RELEASE December2, 2021 Saniona (OMX: SANION), a clinical stage biopharmaceutical company focused on rare diseases, today announcedthat the Chairman and the CEO, as well as additional members of the Board of Directors and executive management team, have purchased 82,000 shares of the company in the open market for a total value of approximately SEK 861,182. Saniona Chairman of the Board J. Donald deBethizy bought 20,000 shares in the company for a total investment of SEK 228,548. President and CEO Rami Levin bought 10,000 shares in the company for a total investment of SEK 100,045. In addition, a total of 52,000 shares were acquired by the other members of Saniona's Board of Directors and executive management team. All transactions have been made in the open market through broker-assisted trades during the period from 19 November 2021 to 2 December 2021. For more information, please contact Trista Morrison, Chief Communications Officer, Saniona. Office: + 1 (781) 810-9227. Email:

Sanionas styrelseordförande J. Donald deBethizy, VD Rami Levin och andra styrelseledamöter och ledande befattningshavare förvärvar aktier i ordinarie börshandel2.12.2021 22:45:00 CET | Pressemelding

PRESSMEDDELANDE 2 december 2021 Saniona (OMX: SANION), ett biofarmaceutiskt företag med klinisk utveckling fokuserad på sällsynta sjukdomar, meddelar idag att styrelsens ordförande, VD och andra ledamöter i styrelsen och ledningsgruppen har förvärvat 82 000 aktier i bolaget i ordinarie börshandel för totalt 861182 SEK. Sanionas styrelseordförande J. Donald deBethizy har köpt 20 000 aktier i bolaget, en investering om totalt 228 548 SEK. Koncernchef och VD Rami Levin har köpt 10 000 aktier i bolaget, en investering om totalt 100 045 SEK. Utöver det har sammanlagt 52 000 ytterligare aktier förvärvats av övriga medlemmar i styrelsen och ledningsgruppen. Alla transaktioner har gjorts i ordinarie börshandel genom etablerade aktiemäklare under perioden 19 november 2021 till 2 december 2021. För ytterligare information, vänligen kontakta Trista Morrison, Chief Communications Officer, Saniona. Kontor: + 1 (781) 810-9227. E-post: trista.morrison@saniona.com Informationen lämnades, genom ovanstå

PubMatic Executive Peter Barry Promoted to Global Role of VP Addressability2.12.2021 22:00:00 CET | Press release

Barry to relocate to New York to lead PubMatic’s audience data business NO-HEADQUARTERS/REDWOOD CITY, Calif., Dec. 02, 2021 (GLOBE NEWSWIRE) -- PubMatic (Nasdaq: PUBM), a sell-side platform that delivers superior outcomes for digital advertising, today announced it has appointed Regional Director, Australia and New Zealand & Head of Audience, APAC, Peter Barry to a global role, naming him VP of Addressability. Barry, who joined the company in 2016, will relocate from Sydney to New York for the new role. He will provide overall leadership across multiple cross functional teams and lead efforts with publishers to ensure they monetise their inventory and drive better outcomes for advertisers and data partners. Barry has been responsible for rolling out the company’s Addressability Suite across APAC, and working with leading data and identity partners in the region. PubMatic’s Addressability Suite includes Audience Encore, which enables data companies, publishers, and advertisers to buy an

PubMatic Executive Peter Barry Promoted to Global Role of VP Addressability2.12.2021 22:00:00 CET | Press release

Barry to relocate to New York to lead PubMatic’s audience data business NO-HEADQUARTERS/REDWOOD CITY, Calif., Dec. 02, 2021 (GLOBE NEWSWIRE) -- PubMatic (Nasdaq: PUBM), a sell-side platform that delivers superior outcomes for digital advertising, today announced it has appointed Regional Director, Australia and New Zealand, Peter Barry to a global role, naming him VP of Addressability. Barry, who joined the company in 2016, will relocate from Sydney to New York for the new role. He will provide overall leadership across multiple cross functional teams and lead efforts with publishers to ensure they monetise their inventory and drive better outcomes for advertisers. Barry has been responsible for rolling out the company’s Addressability Suite across APAC, and working with leading data and identity partners in the region. PubMatic’s Addressability Suite includes Audience Encore, which enables data companies, publishers, and advertisers to buy and sell first-party data and utilize it to c

Bombardier Marks Dual Celebration – NetJets Accepts First Global 7500 Business Jet as Bombardier Delivers 1,000th Global Aircraft2.12.2021 20:05:00 CET | Press release

Delivery of industry’s longest-range business jet marks the first of 20 Global 7500 aircraft to join the NetJets fleet Global 7500 aircraft continues to garner significant interest from customers who value features such as the largest and most unique cabin, innovative technology, unparalleled performance and the smoothest ride MONTRÉAL, Dec. 02, 2021 (GLOBE NEWSWIRE) -- Bombardier announced today the delivery of the 1,000th Global aircraft. The major milestone was reached as the NetJets team led by Patrick Gallagher, President, Sales, Marketing and Services, took delivery of the private aviation company’s first Global 7500 business jet. The addition of a Global 7500 aircraft to the NetJets fleet redefines its large-cabin, long-range offering, and elevates the choice of travel options for its international Owners. With a 7,700 nm (14,260 km) range, NetJets Owners will be able to fly from New York to Beijing or San Francisco to Sydney without refueling stops. The Global 7500 aircraft is

Ultimovacs Granted Orphan Drug Designation by FDA for UV1 Cancer Vaccine in Metastatic Melanoma2.12.2021 19:00:00 CET | Press release

Designation covers UV1 in Metastatic Melanoma as sole agent or part of combination Seven-year market exclusivity after regulatory approval, if received Oslo, 2December2021: Ultimovacs ASA ("Ultimovacs") (OSE ULTI), a clinical stage leader in immune stimulatory vaccines for cancer, today announces that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation (ODD) for the company’s universal cancer vaccine UV1 for the treatment of stage IIB – IV melanoma. UV1, as add-on therapy to checkpoint inhibitors ipilimumab and nivolumab, is currently being studied as first-line treatment for metastatic melanoma in a Phase II trial named INITIUM. The FDA Office of Orphan Products Development (OOPD) supports and advances the development and evaluation of new treatments for rare diseases that affect fewer than 200,000 people in the U.S. Orphan drug designation provides certain benefits, including seven-year market exclusivity upon regulatory approval if received, exemption fro

Mandalay Resources Corporation säljer Cerro Bayo-gruvan till Equus Mining2.12.2021 18:49:34 CET | Pressemelding

TORONTO, Dec. 02, 2021 (GLOBE NEWSWIRE) -- Mandalay Resources Corporation (”Mandalay” eller ”bolaget”) (TSX: MND, OTCQB: MNDJF) har nöjet att meddela att man har slutfört den tidigare aviserade försäljningen av Cerro Bayo-gruvan i Region XI i södra Chile (se Mandalays pressmeddelanden från den 12 oktober 2021 och den 8 oktober 2019). I enlighet med transaktionen förvärvade Equus Mining Limited (”Equus”) Cerro Bayo-gruvan, inklusive dess gruvanläggningar, -tillgångar och -infrastruktur samt en bearbetningsanläggning på 1 500 ton per dag, i utbyte mot 587 502 438 stamaktier i Equus. Mandalay får också en nettoprovision på smältning på 2,25 % på produktionen från Cerro Bayo-gruvan när gruvan har producerat minst 50 000 uns guldekvivalent, som omfattas av en återköpsoption till förmån för Equus. Bolaget förblir ansvarigt för 50 % av de godkända kostnaderna för stängningen av anläggningen vid Cerro Bayo. Dessutom kommer Equus att utse Ryan Austerberry, Mandalays General Manager för Costerfi